Skip to main content

Table 2 Frequency of clinical inactive disease and low disease activity parameters at cross-sectional visit of patients in MTX and biologic era cohorts

From: Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era

 

MTX era (n = 239)

Biologic era (n = 269)

P

Oligoarthritis

(n = 102)

(n = 136)

 

 Patients with physician global assessment = 0

34/100 (34.0)

85/134 (63.4)

< 0.0001

 Patients with active joint count = 0

33/102 (32.4)

90/136 (66.2)

< 0.0001

 Patients with parent global assessment = 0

37/96 (38.5)

61/114 (53.5)

0.0303

 Patients with parent pain assessment = 0

39/95 (41.1)

65/122 (53.3)

0.074

 Patients with ID by Wallace criteria

26/93 (28.0)

54/94 (57.4)

< 0.0001

 Patients with ID by JADAS10

24/85 (28.2)

41/78 (52.6)

0.0015

 Patients with ID by cJADAS10

28/95 (29.5)

63/111 (56.8)

< 0.0001

 Patients with LDA by JADAS10

29/85 (34.1)

43/78 (55.1)

0.0070

 Patients with LDA by cJADAS10

32/95 (33.7)

64/111 (57.7)

0.0010

Polyarthritis

(n = 137)

(n = 133)

 

 Patients with physician global assessment = 0

25/132 (18.9)

76/133 (57.1)

< 0.0001

 Patients with active joint count = 0

25/136 (18.4)

78/133 (58.6)

< 0.0001

 Patients with parent global assessment = 0

33/127 (26.0)

53/113 (46.9)

0.0007

 Patients with parent pain assessment = 0

38/125 (30.4)

58/118 (49.2)

0.0028

 Patients with ID by Wallace criteria

19/129 (14.7)

48/98 (49.0)

< 0.0001

 Patients with ID by JADAS10

19/115 (16.5)

34/84 (40.5)

0.0002

 Patients with ID by cJADAS10

21/122 (17.2)

54/112 (48.2)

< 0.0001

 Patients with LDA by JADAS10

33/115 (28.7)

52/84 (61.9)

< 0.0001

 Patients with LDA by cJADAS10

29/122 (23.8)

60/112 (53.6)

< 0.0001

  1. Data are number positive/number with information available (percentage); reference [11]
  2. MTX methotrexate, ID inactive disease, LDA low disease activity, JADAS10 Juvenile Disease Activity Score 10, cJADAS Clinical Juvenile Disease Activity Score 10